Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sundrug CoSDGCF 75 3-Year EPS without NRI Growth Rate is 6.80% as of Mar. 2026, which is at its 10-year median of 6.80. GuruFocus rates SDGCF with a GF Score™ of 75/100 and a GF Value™ of $36.82. The stock has 1 warning sign investors should review. Among 503 Healthcare Providers & Services companies, Sundrug Co ranks worse than 56.86% on this metric.
During the past 12 months, Sundrug Co's average EPS without NRI Growth Rate was 2.40% per year.
During the past 3 years, the average EPS without NRI Growth Rate was 6.80% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 5.60% per year.
During the past 10 years, the average EPS without NRI Growth Rate was 3.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Sundrug Co was 46.50% per year. The lowest was -16.60% per year. And the median was 6.80% per year.
Sundrug Co (OTCPK:SDGCF) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Sundrug Co 3-Year EPS without NRI Growth Rate Related Terms
Sundrug Co 3-Year EPS without NRI Growth Rate Competitor Comparison
For the Pharmaceutical Retailers subindustry, Sundrug Co's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sundrug Co 3-Year EPS without NRI Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sundrug Co's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Sundrug Co's 3-Year EPS without NRI Growth Rate falls into.
Sundrug Co 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 6.80% mean?
Sundrug Co (SDGCF) has a 3-Year EPS without NRI Growth Rate of 6.80% as of Mar. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Sundrug Co and its competitors. This is near median its historical median of 6.80. According to the industry distribution chart, Sundrug Co ranks #286 out of 503 companies in the Healthcare Providers & Services industry, placing it in the top 56.9%.
Is Sundrug Co's 3-Year EPS without NRI Growth Rate too high?
Sundrug Co's current 3-Year EPS without NRI Growth Rate of 6.80% is near median its 10-year median of 6.80. The Healthcare Providers & Services industry median 3-Year EPS without NRI Growth Rate is 11.00. Sundrug Co's value of 6.80% is 38.2% below this industry median. Based on the distribution chart, Sundrug Co ranks #286 out of 503 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Sundrug Co has a GF Score™ of 75/100, reflecting its overall financial health beyond just this single metric.
How does Sundrug Co's 3-Year EPS without NRI Growth Rate compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Sundrug Co ranks #286 out of 503 companies for 3-Year EPS without NRI Growth Rate. This places Sundrug Co in the lower half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 11.00. Sundrug Co's value of 6.80% is 38.2% below this benchmark. While the company's 10-year median is 6.80 vs. the industry median of 11.00, Sundrug Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EPS without NRI Growth Rate among Healthcare Providers & Services companies is 11.00, based on 503 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sundrug Co's current 3-Year EPS without NRI Growth Rate of 6.80% is 38.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Sundrug Co and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EPS without NRI Growth Rate is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sundrug Co's current 3-Year EPS without NRI Growth Rate is 6.80%, which is near median its own 10-year median of 6.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sundrug Co stock overvalued right now?
Sundrug Co (SDGCF) has a current 3-Year EPS without NRI Growth Rate of 6.80%. The stock's GF Value™ is $36.82, compared to a current price of $28.18 — trading 23.5% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 6.80%, which is near median its 10-year median of 6.80 and 38.2% below the Healthcare Providers & Services industry median of 11.00. Sundrug Co's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Sundrug Co (SDGCF), the current 3-Year EPS without NRI Growth Rate is 6.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sundrug Co (SDGCF) Overvalued in 2026?
Based on GuruFocus' analysis, Sundrug Co stock appears to be undervalued.
The current stock price of $28.18 is trading 23.5% below its estimated GF Value™ of $36.82.
Key valuation signals for SDGCF:
3-Year EPS without NRI Growth Rate: 6.80% (near median its 10-year median of 6.80)
GF Value™: $36.82 vs. price of $28.18 (23.5% below fair value)
Industry Position: 38.2% below the Healthcare Providers & Services median (#286 of 503)
No single metric tells the full story. See the SDGCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sundrug Co Ltd is a Japanese-based company engaged in the operation of drug stores and discount stores. The Group operates through two segments: the Drug Store Business, which mainly sells pharmaceuticals, cosmetics, and daily necessities, and the Discount Store Business, which mainly sells food products, household goods, and other related items. It generates the majority of its revenue from the Drugstore business segment.
75GF Score
Get the complete analysis for SDGCF
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SDGCF has been successfully added to your 
